CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV
12 March 2021. Related: Conference reports, COVID-19: treatment access, COVID-19: investigational drugs, COVID-19.
Conference reports
CROI 2021: Community challenge 6-month CROI pay wall – rather than usual open access…
12 March 2021. Related: Conference reports, Other news.
CROI 2021: Once-daily GSK254 maturation inhibitor as treatment for HIV multidrug resistance
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Dosing for once-weekly oral ART: islatravir plus MK-8507 studies due to start in 2021
12 March 2021. Related: Conference reports, Antiretrovirals.
CROI 2021: Islatravir dosing for once-monthly and annual PrEP: if effective this could end HIV transmission
12 March 2021. Related: Conference reports, HIV prevention and transmission.
CROI 2021: Dolutegravir with recycled tenofovir and lamivudine performs well second-line: primary results from the NADIA trial
12 March 2021. Related: Conference reports, Treatment strategies.
CROI 2021: HIV capsid uncoats in the CD4 nucleus rather than the cytoplasm – viral lifecycle updated…
12 March 2021. Related: Conference reports, Virology.
CROI 2021: Community HIV cure workshops online
12 March 2021. Related: Conference reports, Cure-related research.
R4P virtual conference (2021)
24 February 2021. Related: Conference reports, HIV prevention and transmission.
VRC01 antibody only prevents minority of HIV infections: AMP study results
24 February 2021. Related: Conference reports, HIV prevention and transmission.
Long-acting bNAb is safe and well tolerated and achieves target concentrations in newborns (VRC07-523LS)
24 February 2021. Related: Conference reports, Paediatric care, HIV prevention and transmission.
Promising data for multipurpose technologies to prevent HIV and pregnancy
24 February 2021. Related: Conference reports, Pregnancy, HIV prevention and transmission.
12th International Workshop on HIV paediatrics
24 February 2021. Related: Conference reports.
New LPV/r-based fixed dose HIV combination for young children: first results with Quadrimune 4-in-1
24 February 2021. Related: Conference reports, Paediatric care.
BHIVA 2020 virtual conference now online
22 January 2021. Related: Conference reports.
U=U is supported by a single undetectable viral load in the context of good adherence
22 January 2021. Related: Conference reports, HIV prevention and transmission.
Selected plenary talks and workshops from BHIVA 2020
22 January 2021. Related: Conference reports, On the web.
BHIVA 2020 virtual conference
9 December 2020. Related: Conference reports.
Worryingly low HIV knowledge among health workers at London hospital: 80% unaware of U=U, 36% worried about their risk from patients
9 December 2020. Related: Conference reports, HIV prevention and transmission.
12th International Workshop on HIV paediatrics
9 December 2020. Related: Conference reports.
Dolutegravir dosing for infants and young children
9 December 2020. Related: Conference reports, Paediatric care.
HIV Therapy Glasgow 2020
11 November 2020. Related: Conference reports.
Adverse pregnancy outcomes among Spanish women hospitalised with COVID-19
11 November 2020. Related: Conference reports, Pregnancy, COVID-19: transmission & prevention, COVID-19.
51st World Conference on Lung Health
11 November 2020. Related: Conference reports.
No increase in adverse birth outcomes with IPT-exposure in pregnancy in two African cohorts
11 November 2020. Related: Conference reports, Pregnancy, TB coinfection.
International workshop on clinical pharmacology of HIV, hepatitis, and other antiviral drugs
11 November 2020. Related: Conference reports.
New neonatal liquid formulations of dolutegravir have comparable bioavailability to dispersible paediatric tablet
11 November 2020. Related: Conference reports, Antiretrovirals, Paediatric care, PK and drug interactions.
HIV Therapy Glasgow 2020
15 October 2020. Related: Conference reports.
Capsid inhibitor lenacapavir, dosed six-monthly, has high barrier to drug resistance and no cross-resistance to other classes
14 October 2020. Related: Conference reports, Antiretrovirals.
Single doses of MK-8507 reduce viral load by mean –1.5 log and support once-weekly dosing above 80 mg
14 October 2020. Related: Conference reports, Antiretrovirals.
Weight gain with dolutegravir-based ART in Nigerian cohort
14 October 2020. Related: Conference reports, Side effects.
COVID-19: pathogenesis and treatment
14 October 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
EACS guidelines updated (v.10.1) for Glasgow conference
14 October 2020. Related: Conference reports, Guidelines.
International Workshop on Clinical Pharmacology of HIV, Hepatitis, and Other Antiviral Drugs
14 October 2020. Related: Conference reports, PK and drug interactions.
FTC exposure higher in young transgender men than cisgender controls
14 October 2020. Related: Conference reports, PK and drug interactions, HIV prevention and transmission.
Levels of long-acting anti-HIV bNAb high in infants after 1 or 2 doses – but not high enough
14 October 2020. Related: Conference reports, Paediatric care, PK and drug interactions, HIV prevention and transmission.
23rd International AIDS Conference (AIDS 2020): second reports
28 August 2020. Related: Conference reports.
Capsid inhibitor lenacapavir (GS-6207) allows for 6-monthly dosing
28 August 2020. Related: Conference reports, Antiretrovirals.
Weight gain with integrase inhibitors and TAF: three reports from AIDS 2020
28 August 2020. Related: Conference reports, Side effects.
Dolutegravir non-inferior to efavirenz at week 96 in the NAMSAL study but associated with substantial weight gain
28 August 2020. Related: Conference reports, Treatment strategies.
Switching from efavirenz- to dolutegravir-based ART second-line achieved good rates of suppression: first results from the VISEND study
28 August 2020. Related: Conference reports, Treatment strategies.
Paediatric dolutegravir dosing at AIDS 2020
28 August 2020. Related: Conference reports, Paediatric care.
COVID-19 outcomes in HIV positive people in two large US cohorts
28 August 2020. Related: Conference reports, COVID-19: HIV and COVID-19 coinfection, COVID-19.
AIDS 2020: virtual content now available free and on-demand
28 August 2020. Related: Conference reports, Other news.
Pathways to an HIV cure: online presentations
28 August 2020. Related: Conference reports, Cure-related research.
IAS COVID-19 Conference: introduction
22 July 2020. Related: Conference reports.
Conference opening and making sense of the science
22 July 2020. Related: Conference reports, COVID-19.
HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality
22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
Predictors of response to remdesivir in GS-5773 COVID-19 study
22 July 2020. Related: Conference reports, COVID-19: investigational drugs, COVID-19.
AIDS 2020 online: introduction
22 July 2020. Related: Conference reports.
AIDS 2020: Navigating the website
22 July 2020. Related: Conference reports.
Neural tube defects in two of 1000 conception exposures with dolutegravir: reassuring update from Tsepamo study
22 July 2020. Related: Conference reports, Pregnancy.
Dolutegravir associated with weight gain in African ART programmes: findings from AFRICOS
22 July 2020. Related: Conference reports, Side effects.
ADVANCE 96-week results: dolutegravir weight gain continues, especially in women and when used with TAF – no evidence of a plateau
22 July 2020. Related: Conference reports, Antiretrovirals.
Obesity linked to dolutegravir, especially with TAF, could increase risk of adverse pregnancy outcomes
22 July 2020. Related: Conference reports, Women's health, Pregnancy, Side effects.
Pregnancy meta-analysis: dolutegravir- versus efavirenz-based ART
22 July 2020. Related: Conference reports, Pregnancy.
Long-acting cabotegravir injections are effective as HIV PrEP in gay men and transgender women: results from HPTN 083
22 July 2020. Related: Conference reports, HIV prevention and transmission.
Case report of short-term HIV remission from adding oral nicotinamide to intensified ART
22 July 2020. Related: Conference reports, Cure-related research.
New HIV remission case report at AIDS 2020: full report
22 July 2020. Related: Conference reports, Cure-related research.
23rd International AIDS Conference (AIDS 2020)
26 June 2020. Related: Conference reports.
Conference on Retroviruses and Opportunistic Infections (CROI 2020)
17 April 2020. Related: Conference reports.
Predicted diabetes risk with first-line ART regimens: results from the ADVANCE trial
17 April 2020. Related: Conference reports, Side effects.
Dolutegravir-based ART is safe and effective for pregnant women: first results from the VESTED trial
17 April 2020. Related: Conference reports, Pregnancy.
A step forward for AAV-mediated delivery of bNAbs
17 April 2020. Related: Conference reports, Cure-related research, Basic science and immunology.
10th International Workshop of HIV & Women
17 April 2020. Related: Conference reports.